

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

**Table S1:** Demographic and baseline clinical characteristics

Parameters	Total N=3055	Placebo N=711	Losartan N=721	Placebo N=541	Amlodipine N=534	Irbesartan N=548
Age (yrs.)	59.4 (7.6)	60.2 (7.5)	60.0 (7.4)	58.3 (8.1)	59.1 (7.9)	59.2 (7.1)
Female Gender n, (%)	1067 (34.9)	253 (35.6)	277 (38.4)	156 (28.8)	194 (36.3)	187 (34.1)
Race, n, (%)						
Caucasian	1876 (61.4)	350 (49.2)	345 (47.9)	395 (73.0)	371 (69.5)	415 (75.7)
Black	430 (14.1)	97 (13.6)	118 (16.4)	75 (13.9)	81 (15.2)	59 (10.8)
Hispanic	336 (11.0)	131 (18.4)	132 (18.3)	22 (4.1)	26 (4.9)	25 (4.6)
Asian	319 (10.4)	125 (17.6)	115 (16.0)	26 (4.8)	30 (5.6)	23 (4.2)
Other	94 (3.1)	8 (1.1)	11 (1.5)	23 (4.3)	26 (4.9)	26 (4.7)
Serum creatinine (mg/dL)	1.8 (0.5)	1.9 (0.5)	1.9 (0.5)	1.7 (0.6)	1.7 (0.6)	1.7 (0.5)
eGFR (ml/min/1.73m <sup>2</sup> )	43.8 (15.9)	39.9 (12.7)	39.5 (11.9)	48.0 (18.4)	47.7 (17.7)	46.6 (17.0)
CER (mg/24hr)	1415 (661)	1374 (1041)	1308 (599)	1459 (585)	1446 (558)	1436 (531)
Systolic BP (mmHg)	156 (19.8)	153 (19.9)	152 (18.8)	158 (20.4)	159 (19.3)	160 (19.5)
Diastolic BP (mmHg)	84.8 (11.0)	82.4 (10.7)	82.3 (10.3)	86.8 (11.0)	87.1 (10.8)	86.9 (11.4)
Weight (kg)	84.8 (20.1)	82.1 (21.2)	82.4 (20.6)	87.2 (19.5)	86.3 (19.5)	87.8 (18.1)
UACR (mg/g)	1348 [678, 2615]	1265 [585, 2472]	1182 [545, 2620]	1526 [750, 2670]	1403 [691, 2470]	1478 [803, 2803]
Hemoglobin (mg/dL)	12.8 (1.9)	12.5 (1.8)	12.5 (1.8)	13.0 (1.9)	12.9 (1.9)	13.0 (1.9)
Urea Nitrogen (mg/dL)	31.2 (12.3)	32.3 (12.3)	32.5 (12.2)	29.7 (12.3)	29.8 (11.8)	30.8 (12.7)
Potassium (mmol/L)	4.6 (0.5)	4.6 (0.5)	4.6 (0.5)	4.6 (0.5)	4.6 (0.5)	4.6 (0.5)
Uric acid (mg/dL)	6.8 (1.8)	6.7 (1.7)	6.7 (1.7)	6.8 (1.9)	6.8 (1.8)	6.8 (1.9)
Calcium (mg/dL)	9.3 (0.5)	9.4 (0.5)	9.4 (0.5)	9.2 (0.6)	9.2 (0.5)	9.2 (0.5)
Phosphate (mg/dL)	3.8 (0.6)	3.9 (0.6)	3.9 (0.6)	3.8 (0.6)	3.8 (0.7)	3.8 (0.6)
CVD history (yes), n, (%)	1376 (45.0)	311 (43.7)	330 (45.8)	238 (44.0)	238 (44.6)	259 (47.3)

Abbreviations: BP, blood pressure; eGFR, estimated glomerular filtration rate; CER: creatinine excretion rate; UACR, urinary albumin to creatinine ratio; CVD, cardiovascular disease; Note: Values for categorical variables are reported as percentages; values for continuous variables are reported as mean ± standard deviation or median [interquartile range]

**Table S2:** Difference in the time to RRT and eGFR11 in the population with the sum of square of the residuals below the individual based eGFR regression below the median.

	eGFR <sub>11</sub> before RRT		eGFR <sub>11</sub> after RRT		Accuracy P <sub>90</sub> (%)
	Patients with RRT (N)	Median (25 <sup>th</sup> – 75 <sup>th</sup> P) time difference (days)	Patients with RRT (N)	Median (25 <sup>th</sup> – 75 <sup>th</sup> P) time difference (days)	
eGFR <sub>11</sub> vs. RRT	259	152 [82 – 261]	124	152 [51 – 414]	30.5
eGFR <sub>11-first</sub> vs. RRT	79	161 [115 – 276]	n/a	n/a	12.7
eGFR <sub>11</sub> vs. eGFR <sub>11-first</sub>	50	47 [27 – 64]	30	50 [21 – 82]	81.3

Abbreviations: eGFR<sub>11</sub>, time to eGFR 11 mL/min/1.73m<sup>2</sup> based on individual's eGFR slope; eGFR<sub>11-first</sub>, time to first eGFR 11 measurement confirmed by the second measurement of reaching eGFR<sub>11</sub>; P, Percentile

**Table S3:** Difference in the time to RRT and eGFR15 in patients who either reached eGFR<sub>15</sub> before or after RRT

	eGFR <sub>15</sub> before RRT		eGFR <sub>15</sub> after RRT		Accuracy P <sub>90</sub> (%)
	Patients with RRT (N)	Median (25 <sup>th</sup> – 75 <sup>th</sup> P) time difference (days)	Patients with RRT (N)	Median (25 <sup>th</sup> – 75 <sup>th</sup> P) time difference (days)	
eGFR <sub>15</sub> vs. RRT	370	241 [140 – 364]	78	228 [100 – 436]	14.8
eGFR <sub>15-first</sub> vs. RRT	220	240 [161 – 385]	n/a	n/a	6.4
eGFR <sub>15</sub> vs. eGFR <sub>15-first</sub>	152	44 [19 – 85]	68	42 [23 – 80]	78.2

Abbreviations: eGFR<sub>15</sub>, time to eGFR 15 mL/min/1.73m<sup>2</sup> based on individual's eGFR slope; eGFR<sub>15-first</sub>, time to first eGFR 15 measurement confirmed by the second measurement of reaching eGFR<sub>15</sub>; P, Percentile